Johnson & Johnson $JNJ Stock Purchased by Hollow Brook Wealth Management LLC

Key Points

• Hollow Brook Wealth Management increased its Johnson & Johnson stake by 23.7% in the third quarter, bringing its holdings to 50,900 shares valued at approximately $13.5 million. Institutional investors and hedge funds collectively own 69.55% of JNJ.
• Johnson & Johnson reported quarterly revenue of $25.40 billion and adjusted earnings of $2.59 per share, exceeding analyst expectations. The company issued full-year 2026 earnings guidance of $11.05–$11.15 per share.
• The company declared a quarterly dividend of $1.34 per share, equivalent to an annualized $5.36 dividend and a 2.0% yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $275.92, close to the reported share price of $270.81.

Hollow Brook Wealth Management LLC grew its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 23.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 50,900 shares of the company's stock after buying an additional 9,742 shares during the quarter. Johnson & Johnson accounts for approximately 2.3% of Hollow Brook Wealth Management LLC's portfolio, making the stock its 7th biggest position. Hollow Brook Wealth Management LLC's holdings in Johnson & Johnson were worth $13,475,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in JNJ. National Pension Service raised its position in Johnson & Johnson by 1.3% in the second quarter. National Pension Service now owns 5,226,968 shares of the company's stock worth $1,327,493,000 after acquiring an additional 67,484 shares in the last quarter. IFP Advisors Inc boosted its position in shares of Johnson & Johnson by 8.8% during the 2nd quarter. IFP Advisors Inc now owns 38,760 shares of the company's stock worth $9,844,000 after purchasing an additional 3,133 shares in the last quarter. Elefante Mark B boosted its position in shares of Johnson & Johnson by 9.8% during the 2nd quarter. Elefante Mark B now owns 28,686 shares of the company's stock worth $7,285,000 after purchasing an additional 2,563 shares in the last quarter. Gradient Investments LLC grew its stake in shares of Johnson & Johnson by 9.9% during the 2nd quarter. Gradient Investments LLC now owns 152,831 shares of the company's stock worth $38,815,000 after purchasing an additional 13,737 shares during the period. Finally, AMG Asset Management Group Inc. grew its stake in shares of Johnson & Johnson by 172.0% during the 3rd quarter. AMG Asset Management Group Inc. now owns 3,852 shares of the company's stock worth $1,020,000 after purchasing an additional 2,436 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Down 0.9%

Shares of NYSE JNJ opened at $270.81 on Tuesday. The firm has a market cap of $651.93 billion, a P/E ratio of 41.03, a price-to-earnings-growth ratio of 2.68 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. Johnson & Johnson has a 1 year low of $185.12 and a 1 year high of $282.02. The firm's 50 day moving average price is $265.74 and its 200 day moving average price is $247.22.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company's revenue was up 5.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson's dividend payout ratio is currently 81.21%.

Analysts Set New Price Targets

JNJ has been the topic of a number of research analyst reports. Royal Bank Of Canada decreased their price objective on shares of Johnson & Johnson from $290.00 to $280.00 and set an "outperform" rating on the stock in a report on Wednesday, October 14th. Bank of America reaffirmed a "neutral" rating and issued a $278.00 target price on shares of Johnson & Johnson in a report on Tuesday, September 29th. Guggenheim reiterated a "buy" rating and set a $287.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 7th. Scotiabank reissued an "outperform" rating and set a $305.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. Finally, Erste Group Bank cut Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $275.92.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares of the company's stock, valued at $4,367,458. The trade was a 48.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 64,515 shares of company stock valued at $17,271,766 over the last three months. 0.16% of the stock is owned by company insiders.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: New real-world and observational analyses presented at the TCT 2026 symposium found lower in-hospital and short-term mortality among high-risk percutaneous coronary intervention patients supported by Impella pumps. The findings covered 1,379 patients in U.S. and European hospitals and compared favorably with results from the CHIP-BCIS3 study. Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI
• Positive Sentiment: A separate report cited a 94% success rate in a coronary-device trial, adding to evidence that Impella could improve outcomes in complex coronary procedures. Stronger clinical support could help J&J expand adoption of the devices and reinforce its medical-technology growth strategy. Johnson & Johnson reports 94% success rate in trial of coronary artery device
• Positive Sentiment: Clinicians also reviewed progress in the ongoing PROTECT IV trial, which is expected to provide additional evidence for Impella-supported high-risk procedures. Further positive results could improve confidence in the product’s long-term commercial potential. What Is Johnson & Johnson Signaling With Its New Impella Heart Pump Data?
• Neutral Sentiment: Exchange-traded funds purchased approximately $35.1 million of JNJ shares on October 29, suggesting institutional demand, though the transaction alone does not establish a lasting change in investor sentiment. ETFs Are Buying Johnson & Johnson
• Negative Sentiment: Some coverage questioned whether JNJ is fully valued after strong recent performance, including a reported 6.71% 30-day return and 31.76% year-to-date gain. That raises the risk that positive Impella news is already reflected in the stock and could limit near-term upside. Johnson & Johnson As Impella Data Fuels The Story, Is The Stock Fully Valued?

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.